Genetic polymorphisms in catalase and CYP1B1 determine DNA adduct formation by benzo(a)pyrene ex vivo

Marten A. Schults¹, Roland K. Chiu¹,³, Peter W. Nagle¹,³, Lonneke C. Wilms³, Jos C. Kleijnjans¹, Frederik J. van Schooten¹ and Roger W. Godschalk¹,⋆
¹Department of Toxicology, NUTRIM-School for Nutrition, Toxicology and Metabolism, Maastricht University, PO Box 616, 6200 MD, Maastricht, The Netherlands and ³Department of Toxicogenomics, GROW-School for Oncology and Developmental Biology, Maastricht University, PO Box 616, 6200 MD, Maastricht, The Netherlands.
³Present address: Department of Radiation Oncology, University Medical Center Groningen, PO Box 50001, 9700 RB Groningen, The Netherlands
⋆To whom correspondence should be addressed. Tel: +31 43 3881104; Fax: +31 43 3884146; Email: R.Godschalk@maastrichtuniversity.nl

Received on June 2, 2012; revised on September 26, 2012; accepted on October 19, 2012

Genetic polymorphisms can partially explain the large inter-individual variation in DNA adduct levels following exposure to polycyclic aromatic hydrocarbons. Effects of genetic polymorphisms on DNA adduct formation are difficult to assess in human studies because exposure misclassification attenuates underlying relationships. Conversely, ex vivo studies offer the advantage of controlled exposure settings, allowing the possibility to better elucidate genotype–phenotype relationships and gene–gene interactions. Therefore, we exposed lymphocytes of 168 non-smoking volunteers ex vivo to the environmental pollutant benzo(a)pyrene (BaP) and BaP-related DNA adducts were quantified. Thirty-four genetic polymorphisms were assessed in genes involved in carcinogen metabolism, oxidative stress and DNA repair. Polymorphisms in catalase (CAT, rs1001179) and cytochrome P450 IBI (CYP1B1, rs1800440) were significantly associated with DNA adduct levels, especially when combined. Moreover, reverse transcription–polymerase chain reaction (RT–PCR) analysis in a subset of 30 subjects revealed that expression of catalase correlated strongly with expression of CYP1B1 (R = 0.92, P < 0.001). To further investigate the mechanism by which catalase influences CYP1B1 and how they simultaneously affect BaP-related DNA adduct levels, catalase expression was transiently knocked down in the human lung epithelial cell line A549. Although catalase knockdown did not immediately change CYP1B1 gene expression, recovery of catalase expression 8 h after the knockdown coincided with a 2.2-fold increased expression of CYP1B1 (P < 0.05). We conclude that the genetic polymorphism in the promoter region of CAT may determine the amount and activity of catalase, which may subsequently regulate the expression of CYP1B1. As a result, both genetic polymorphisms modulate DNA adduct levels in lymphocytes by BaP ex vivo.

Introduction

Genetic stability is challenged by many factors, including exposure to genotoxic chemical compounds such as polycyclic aromatic hydrocarbons (PAHs). PAHs such as benzo(a)pyrene (BaP) are widely distributed environmental contaminants that are able to upregulate a multitude of genes, including the cytochrome P450 isoforms CYP1A1 and CYP1B1. These enzymes metabolise BaP to more soluble and excretable products but at the same time activate certain metabolites into the highly reactive form BaP-7,8-dihydriodiol-9,10-epoxide (BPDE) that is able to bind to DNA to form bulky DNA adducts. When unrepaired, DNA adducts can lead to mutations that initiate carcinogenesis. Therefore, bulky DNA adducts are markers for both the exposure to genotoxic aromatic compounds and the ability of the individual to metabolically activate carcinogens and to repair DNA damage (1). Nevertheless, individuals with similar exposures have highly different DNA adduct levels (2), which may in part be explained by genetic polymorphisms in genes involved in the process of DNA adduct formation and repair. These variations have been studied extensively and multiple genetic polymorphisms affecting BPDE-DNA adducts have been identified, including genes involved in metabolism (CYP1A1, GSTM1, GSTT1 (3–5)), DNA repair (ERCC1, XPD (6)) and oxidative stress (7).

We previously showed that single genetic polymorphisms are unable to adequately account for the inter-individual variation but rather by combinations of relevant genetic polymorphisms and the level of exposure (8). The level of exposure is often insufficiently characterised in large epidemiological studies that investigate the impact of genetic variation on DNA damage or disease, leading to misclassification and attenuation of underlying relationships. On the other hand, exposure can be well controlled in in vitro or ex vivo studies, offering the possibility to elucidate genotype–phenotype relationships and gene–gene interactions more reliably. Interestingly, the level of BPDE-DNA adduct formation ex vivo in lymphocytes was related to lung cancer risks (9), further offering support for using ex vivo experiments to investigate sources of inter-individual variation in cancer susceptibility. Therefore, lymphocytes of healthy volunteers were incubated with 1 μM BaP for 18 h. We assessed 34 single nucleotide polymorphism (SNPs) based on a priori knowledge (10) and determined which SNPs were responsible for differences in BaP-related DNA adduct levels. One SNP in catalase (CAT, rs1001179) and one in CYP1B1 (rs1800440) had a significant impact on BaP-related DNA adducts formation and further experiments were performed to study genotype–phenotype relationships and gene–gene interactions in lung epithelial cells (A549) in which catalase was transiently knocked down by siRNA.

Materials and methods

Study population

The previously described study population consisted of 114 females and 54 males, aged 18–45 with an average of 29 and 28 years for males and females, respectively (10). These healthy volunteers were recruited through advertisements in local newspapers and were non-smokers and did not use medication (except for oral contraceptives by all female volunteers) or vitamin supplementation. Subjects were fully informed about the details of the study and gave their written informed consent. The Medical Ethical Committee of Maastricht University and the Academic Hospital Maastricht approved the protocol.
Collection and treatment of samples
Venous blood samples were collected between 8 and 9 AM in 10 ml vacuum lithium heparin tubes (venoject II, Terumo-Europe, Leuren, Belgium). For isolation of lymphocytes, heparinised blood was 1:1 diluted with phosphate-buffered saline (PBS, pH 7.4) and layered on Lymphoprep™ (Axis-shield, Oslo, Norway) in a leukocyte tube (Greiner Bio-one, Frickenhausen, Germany). Lymphocytes were separated by 20 min 860g centrifugation at room temperature and subsequently washed and treated with 25 µM hydrogen peroxide for 1 h at 37°C or 1 µM BaP for 18 h at 37°C as described by Wilms et al. (10).

Comet assay
Following incubation with hydrogen peroxide, cell suspensions were diluted 1:4 in 0.5% low melting-point agarose and added to microscope slides pre-coated with a layer of 1.5% normal melting-point agarose and put at 4°C for 45 min. Cells were lysed (0.25 M NaOH, 0.1 M EDTA, 0.01 M Tris, 2.5 M NaCl, 1% Triton X-100 and 10% DMSO, adjusted to pH 10) for 1 h at 4°C, washed with PBS, placed in electrophoresis buffer (1 mM EDTA, 300 mM NaOH, pH 13) for 40 min for denaturation and subsequently separated by electrophoresis for 30 min at 25 V and 300 mA. The slides were washed twice with PBS for 10 min and stained with ethidium bromide (10 µg/ml) and visualised using a Zeiss Axioskop fluorescence microscope. About 50 randomly selected nuclei were analysed per slide using the Comet assay III software program (Perceptive Instruments, Havervill, UK).

Genotyping
DNA was isolated from lymphocytes by standard phenol extraction procedures. The Cancer SNP 500 database was used to obtain DNA sequences and allele frequencies (http://snpg00.cancer.nci.nih.gov) of 34 SNPs (Supplementary Table I, available at Mutagenesis Online). SNPs were analysed using a multiplex PCR method developed by Knaapen et al. (11) and further refined by Ketelslegers et al. (8). Genotyping of 10% of the samples was performed in duplicate to ensure reliability.

ΔΔCt method. The stably expressed gene

Results
SNPs in CYP1B1 and catalase are linked to ex vivo BaP-related DNA adduct formation
Of the 34 SNPs, we obtained (Supplementary Table I, available at Mutagenesis Online); only two were related to BaP-related DNA adduct levels ex vivo. These were the polymorphisms in CYP1B1 (rs1800440) and catalase (rs1001179). Individuals carrying one or both variant allele of CYP1B1-N453S showed a statistically significant lower amount of BaP-related DNA adducts compared with individuals that were homozygous for the wild-type allele (Figure 1A). Individuals carrying one or both variant alleles of CAT C-262T had higher levels of BaP-related DNA adducts compared with individuals that were homozygous for the wild-type allele (Figure 1B). Lowest
BaP-related DNA adduct levels were observed in subjects that carried the combined homozygous \textit{CYP1B1} variant alleles and the homozygous wild-type alleles for \textit{CAT}.

\textbf{Phenotypic effect of SNP in promoter region of \textit{CAT}}

As the SNP in catalase is located in the promoter region, we sought to determine whether gene expression would be affected. Therefore, mRNA levels were determined (Figure 2) in unexposed peripheral blood lymphocytes of 30 subjects selected on basis of their genotype (10 of each genotype). Individuals homozygous for the wild-type allele of \textit{CAT} (CC) had ~1.9-fold lower catalase mRNA levels than individuals that were homozygous for the variant allele ($P < 0.001$). To assess whether increased expression of CAT also resulted in a concomitant increased catalase activity, the ability to prevent single-strand breaks (SSB) induced by H$_2$O$_2$ was determined (Figure 3). To this end, lymphocytes were incubated with H$_2$O$_2$ and a comet assay was performed to measure SSB. Samples from individuals that were homozygous for the wild-type allele of \textit{CAT} (CC) had ~1.5-fold higher amount of SSB than samples from subjects carrying at least one T-allele ($P < 0.001$). This is consistent with the lower mRNA expression levels observed in lymphocytes of subjects carrying at least one T allele.

\textbf{Expression of catalase strongly correlated with expression of \textit{CYP1B1}}

To further define how catalase expression affects BaP-related DNA adduct levels, catalase mRNA levels were correlated with the expression of \textit{CYP1B1} and a strong significant correlation was observed ($P < 0.001$, \(R = 0.92\), Figure 4). The genetic polymorphism in \textit{CAT}, which regulates the level of gene expression of CAT, thus seems to co-regulate the expression of \textit{CYP1B1} in human lymphocytes. Indeed, the expression of \textit{CYP1B1} was approximately 2-fold higher in carriers of the \textit{CAT}TT-genotype than in the CC-genotype subjects but this did not reach statistical significance ($P = 0.08$). No difference was observed between \textit{CYP1B1} mRNA expression of male and female volunteers (data not shown).

\textbf{In vitro modulation of catalase expression alters \textit{CYP1B1} mRNA levels}

To further investigate the mechanism by which catalase affects \textit{CYP1B1} gene expression, A549 lung epithelial cells lines were used to investigate the effect of changing catalase gene expression on \textit{CYP1B1}. A statistically significant correlation in the expression of catalase and \textit{CYP1B1} was observed in unexposed cells ($P < 0.001$, \(R = 0.96\), Figure 4). From the \textit{ex vivo} observation, we hypothesised that knocking down the expression of catalase would also downregulate the expression of \textit{CYP1B1}. After knockdown of catalase expression, only 15% of the catalase mRNA remained following 24 h of siRNA treatment (Figure 5). The expected simultaneous downregulation of \textit{CYP1B1} gene expression was not observed. On the other hand, the removal of the siRNA resulted in the recovery of \textit{CAT} expression, which coincided with a 2.2-fold upregulation of \textit{CYP1B1} expression ($P < 0.001$).

Downregulation of catalase is expected to increase intracellular oxidative stress; the resulting activation of the nuclear erythroid 2-related factor 2 (Nrf2) pathway may be a potential
estrogen metabolism (19). Interestingly, estrogen metabolism CYP1B1 activity can result in a decreased genotoxicity from observed in individuals with the 453S allele (18). Decreased rate of CYP1B1 and subsequent decreased CYP1B1 activity (16,17). This could be explained by the increased degradation cancer risks and aggressiveness of hormone-dependent cancers N453S polymorphism has previously been linked to altered difference in BaP-related DNA adduct formation. The in determining the levels of BaP-related DNA adducts interact that genetic polymorphisms in CYP1B1 catalase and further elucidate genotype–phenotype relationships and report because exposure misclassification attenuates underlying rela-

Discussion

PAHs such as BaP are carcinogens that humans are unknow-
ingly and/or unavoidably exposed to on a daily basis. The ability of an individual to cope with these carcinogens may determine the risk of developing cancer. This intrinsic risk varies within the population and genetic polymorphisms in genes such as those involved in BaP metabolism may be a source of this disparity. Previous studies showed that certain genetic polymorphisms are related to an increase in adduct formation (3,15). However, phenotypic effects of certain genetic polymorphisms are difficult to assess in epidemiological studies because exposure misclassification attenuates underlying relationships. Therefore, we exposed cells to a single compound to further elucidate genotype–phenotype relationships and report that genetic polymorphisms in catalase and CYP1B1 interact in determining the levels of BaP-related DNA adducts ex vivo.

Of the 34 polymorphisms investigated, only two resulted in a difference in BaP-related DNA adduct formation. The CYP1B1-N453S polymorphism has previously been linked to altered cancer risks and aggressiveness of hormone-dependent cancers (16,17). This could be explained by the increased degradation rate of CYP1B1 and subsequent decreased CYP1B1 activity observed in individuals with the 453S allele (18). Decreased CYP1B1 activity can result in a decreased genotoxicity from estrogen metabolism (19). Interestingly, estrogen metabolism shows large overlap with the metabolism of PAH, such as BaP. CYP1B1 is also capable of metabolising BaP to its reactive metabolites. This metabolic activation is usually ascribed to CYP1A1 but the expression of CYP1A1 is minimal in lymphocytes. In our sample population, expression of CYP1A1 was more than 18-fold lower than the expression of CYP1B1 (data not shown). The CYP1B1-N453S variant alleles appear to be protective since individuals carrying one or two variant alleles had lower levels of BaP-related DNA adducts after ex vivo exposure to BaP (Figure 1).

The other polymorphism that influenced BaP-related DNA adduct formation in our population was catalase C-262T (rs1001179). Catalase reduces oxidative stress by catalysing the conversion of H2O2 into water and oxygen. The location of this polymorphism in the promoter suggests that it is involved in the regulation of catalase gene expression. Therefore, we measured catalase mRNA levels in lymphocytes from indi-

Fig. 5. CYP1B1 mRNA levels are increased upon recovery of catalase mRNA levels 8 h after a transient knockdown. mRNA levels of catalase, CYP1B1 and NQO1 in A549 were measured after no treatment (white), 24 h of catalase siRNA (striped), 24 h of catalase siRNA followed by 8 h recovery without siRNA (black). Data are presented as mean ± standard error of the mean fold increase compared with no treatment (n = 3 for each bar, *P < 0.001).
significantly induced AhR, CYP1A1 and CYP1B1 transcription in mouse embryonic fibroblasts (14). In response to oxidative stress, Nrf2 is activated and upregulates antioxidant and detoxifying genes, including NQO1 (25). In our study, the increase in NQO1 mRNA levels suggests that the knockdown of catalase is indeed related to increased oxidative stress levels and activation of Nrf2. The opposing effects of both NF1 and Nrf2 eventually resulted in an initial unchanged CYP1B1 gene expression. However, when catalase mRNA levels started to increase after removal of the siRNA, oxidative stress quickly decreased and the Nrf2 was deactivated (since NQO1 expression went back to baseline levels). We speculate that as a result of the restored expression of catalase, CYP1B1 expression further increased and was over-compensated (>2-fold increased expression). These in vitro studies confirm that catalase affects CYP1B1 gene expression.

We propose a model in which the genetic polymorphism in the promoter region of CAT-262C→T determines the amount of intracellular oxidative stress, which co-regulates the expression of CYP1B1 by reducing the amount of H2O2 present in the cells. Oxidative stress would inactivate or activate relevant transcription factors (NF1 and Nrf2). The genetic polymorphisms in CYP1B1 subsequently modulates BaP metabolism ex vivo in lymphocytes. Thus, the SNP in CAT determines the amount of CYP1B1, whereas the SNP in CYP1B1 determines its activity. These ex vivo data indicate that inter-individual variations in DNA adduct levels depend on gene–gene interactions, which need further attention for application in in vivo studies. Understanding gene–gene interactions allows the identification of relevant combinations of SNPs to assess an individual’s cancer susceptibility.

Supplementary data

Supplementary Tables I and II are available at Mutagenesis Online.

Funding

Province of Limburg, the Netherlands and the European Network of Excellence (NoE); Environmental cancer, nutrition and individual susceptibility (ECNIS); sixth Framework programme (FP6), FOOD-CT-2005–513943.

Conflicts of interest: none declared.

References